Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced soli…

Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer

Estimated

~$10 – $8,750

Aminex Therapeutics, Inc.NCT07287917

Phase 2

A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)

The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrog…

Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more

Estimated

~$10 – $7,500

Kristina A. FanucciNCT07222215

Observational

STRIDE: Evidence-Based Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy

The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to …

Hormone Receptor Positive Breast Cancer

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07759947

Phase 1

Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Patients With Advanced Breast Cancer

A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.

Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast Cancer

Estimated

~$10 – $7,500

Radionetics OncologyNCT07121244

Phase 1

Phase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer

A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.

Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast CancerHormone Receptor Positive Breast Adenocarcinoma

Estimated

~$10 – $7,500

Radionetics OncologyNCT06745804